Bright Minds Biosciences Inc Market Cap ($203.11 Million)
Market Cap & Net Worth: Bright Minds Biosciences Inc (DRUG)
Bright Minds Biosciences Inc market cap. Bright Minds Biosciences Inc (NASDAQ:DRUG) has a market capitalization of $203.11 Million ($203.11 Million) as of November 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16267 globally and #3870 in its home market, demonstrating a -62.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bright Minds Biosciences Inc's stock price $20.70 by its total outstanding shares 9812061 (9.81 Million). Also see Bright Minds Biosciences Inc (DRUG) cash flow conversion for how efficiently the company converts equity into cash flow.
Bright Minds Biosciences Inc Market Cap History (2021–2026)
Bright Minds Biosciences Inc market cap history from 2021 to 2026. Data shows change from $155.52 Million to $203.11 Million (-4.61% CAGR). Check today's stock price for Bright Minds Biosciences Inc for real-time trading data and today's change.
Index Memberships
Bright Minds Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.01% | #440 of 976 |
|
NASDAQ Composite
IXIC
|
$38.55 Trillion | 0.00% | #1587 of 3165 |
Weight: Bright Minds Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bright Minds Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bright Minds Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Bright Minds Biosciences Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DRUG by Market Capitalization
Companies near Bright Minds Biosciences Inc in the global market cap rankings as of November 7, 2026. Also see Bright Minds Biosciences Inc total assets for a full breakdown of the balance sheet.
Key companies related to Bright Minds Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of Bright Minds Biosciences Inc (2021–2026)
Market capitalization of Bright Minds Biosciences Inc from 2021 to today. Between 2021 and today, Bright Minds Biosciences Inc's market cap moved from $155.52 Million to $ 203.11 Million, with a yearly change of -4.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $203.11 Million | -73.48% |
| 2025 | $765.73 Million | +116.66% |
| 2024 | $353.43 Million | +2418.88% |
| 2023 | $14.03 Million | -61.35% |
| 2022 | $36.30 Million | -76.66% |
| 2021 | $155.52 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Bright Minds Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $203.11 Million USD |
| MoneyControl | $203.11 Million USD |
| MarketWatch | $203.11 Million USD |
| marketcap.company | $203.11 Million USD |
| Reuters | $203.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more